Literature DB >> 15356338

Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30).

S C Burgess1, J R Young, B J G Baaten, L Hunt, L N J Ross, M S Parcells, P M Kumar, C A Tregaskes, L F Lee, T F Davison.   

Abstract

Animal models are essential for elucidating the molecular mechanisms of carcinogenesis. Hodgkin's and many diverse non-Hodgkin's lymphomas overexpress the Hodgkin's disease antigen CD30 (CD30(hi)), a tumor necrosis factor receptor II family member. Here we show that chicken Marek's disease (MD) lymphoma cells are also CD30(hi) and are a unique natural model for CD30(hi) lymphoma. Chicken CD30 resembles an ancestral form, and we identify a previously undescribed potential cytoplasmic signaling domain conserved in chicken, human, and mouse CD30. Our phylogeneic analysis defines a relationship between the structures of human and mouse CD30 and confirms that mouse CD30 represents the ancestral mammalian gene structure. CD30 expression by MD virus (MDV)-transformed lymphocytes correlates with expression of the MDV Meq putative oncogene (a c-Jun homologue) in vivo. The chicken CD30 promoter has 15 predicted high-stringency Meq-binding transcription factor recognition motifs, and Meq enhances transcription from the CD30 promoter in vitro. Plasma proteomics identified a soluble form of CD30. CD30 overexpression is evolutionarily conserved and defines one class of neoplastic transformation events, regardless of etiology. We propose that CD30 is a component of a critical intracellular signaling pathway perturbed in neoplastic transformation. Specific anti-CD30 Igs occurred after infection of genetically MD-resistant chickens with oncogenic MDV, suggesting immunity to CD30 could play a role in MD lymphoma regression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356338      PMCID: PMC518847          DOI: 10.1073/pnas.0305789101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Peripheral T lymphocyte cytokine profile (IFNgamma, IL-2, IL-4) and CD30 expression/release during measles infection.

Authors:  F Vinante; M Krampera; L Morosato; A Rigo; S Romagnani; G Pizzolo
Journal:  Haematologica       Date:  1999-08       Impact factor: 9.941

Review 2.  Cancer vaccine: identification of human tumor antigens by SEREX.

Authors:  Y T Chen
Journal:  Cancer J       Date:  2000-05       Impact factor: 3.360

3.  Structure of the Hodgkin's lymphoma-associated human CD30 gene and the influence of a microsatellite region on its expression in CD30(+) cell lines.

Authors:  H Dürkop; M Oberbarnscheidt; U Latza; S Bulfone-Paus; H Krause; T Pohl; H Stein
Journal:  Biochim Biophys Acta       Date:  2001-06-28

4.  MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.

Authors:  B Lethé; P van der Bruggen; F Brasseur; T Boon
Journal:  Melanoma Res       Date:  1997-08       Impact factor: 3.599

5.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.

Authors:  M Röpke; J Hald; P Guldberg; J Zeuthen; L Nørgaard; L Fugger; A Svejgaard; S Van der Burg; H W Nijman; C J Melief; M H Claesson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

6.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data.

Authors:  K Quandt; K Frech; H Karas; E Wingender; T Werner
Journal:  Nucleic Acids Res       Date:  1995-12-11       Impact factor: 16.971

7.  Adult T-cell leukemia/lymphoma in which the pathohistological diagnosis was identical to that of Ki-1 positive anaplastic large cell lymphoma.

Authors:  T Takahara; K Masutani; E Kajiwara; S Sadoshima; M Misago; Y Sasaguri; K Onoyama
Journal:  Intern Med       Date:  1999-10       Impact factor: 1.271

8.  Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation.

Authors:  O Devergne; E Hatzivassiliou; K M Izumi; K M Kaye; M F Kleijnen; E Kieff; G Mosialos
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

9.  Non-Hodgkin's lymphoma: in a class all its own.

Authors:  C P Titcomb
Journal:  J Insur Med       Date:  2001

10.  Demonstration of a tumor-associated surface antigen in Marek's disease.

Authors:  R L Witter; E A Stephens; J M Sharma; K Nazerian
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

View more
  38 in total

1.  Elevated serum levels of CCL17 correlate with increased peripheral blood platelet count in patients with active tuberculosis in China.

Authors:  Yonghong Feng; Hongyun Yin; Guangliang Mai; Ling Mao; Jun Yue; Heping Xiao; Zhongyi Hu
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

2.  Revaccination with Marek's disease vaccines induces productive infection and superior immunity.

Authors:  Changxin Wu; Junji Gan; Qiao Jin; Chuangfu Chen; Ping Liang; Yantao Wu; Xuefen Liu; Li Ma; Fred Davison
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

3.  The oncogenic microRNA OncomiR-21 overexpressed during Marek's disease lymphomagenesis is transactivated by the viral oncoprotein Meq.

Authors:  Grégoire Stik; Ginette Dambrine; Sébastien Pfeffer; Denis Rasschaert
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

4.  Identification of an intercistronic internal ribosome entry site in a Marek's disease virus immediate-early gene.

Authors:  Abdessamad Tahiri-Alaoui; Lorraine P Smith; Suzan Baigent; Lydia Kgosana; Lawrence J Petherbridge; Luke S Lambeth; William James; Venugopal Nair
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

5.  A systematic analysis of miRNA transcriptome in Marek's disease virus-induced lymphoma reveals novel and differentially expressed miRNAs.

Authors:  Ling Lian; Lujiang Qu; Yanmei Chen; Susan J Lamont; Ning Yang
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

6.  DNMT gene expression and methylome in Marek's disease resistant and susceptible chickens prior to and following infection by MDV.

Authors:  Fei Tian; Fei Zhan; Nathan D VanderKraats; Jeffrey F Hiken; John R Edwards; Huanmin Zhang; Keji Zhao; Jiuzhou Song
Journal:  Epigenetics       Date:  2013-03-28       Impact factor: 4.528

7.  Alternative splicing and nonsense-mediated decay regulate telomerase reverse transcriptase (TERT) expression during virus-induced lymphomagenesis in vivo.

Authors:  Souheila Amor; Sylvie Remy; Ginette Dambrine; Yves Le Vern; Denis Rasschaert; Sylvie Laurent
Journal:  BMC Cancer       Date:  2010-10-21       Impact factor: 4.430

8.  Mapping QTL affecting resistance to Marek's disease in an F6 advanced intercross population of commercial layer chickens.

Authors:  Eliyahu M Heifetz; Janet E Fulton; Neil P O'Sullivan; James A Arthur; Hans Cheng; Jing Wang; Morris Soller; Jack C M Dekkers
Journal:  BMC Genomics       Date:  2009-01-14       Impact factor: 3.969

9.  Genotype-dependent tumor regression in Marek's disease mediated at the level of tumor immunity.

Authors:  Shyamesh Kumar; Joram J Buza; Shane C Burgess
Journal:  Cancer Microenviron       Date:  2009-03-18

10.  The Chicken Gene Nomenclature Committee report.

Authors:  David W Burt; Wilfrid Carrë; Mark Fell; Andy S Law; Parker B Antin; Donna R Maglott; Janet A Weber; Carl J Schmidt; Shane C Burgess; Fiona M McCarthy
Journal:  BMC Genomics       Date:  2009-07-14       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.